NeuroBo licenses NB-01 to MThera Pharma for diabetic neuropathy; terms undisclosed

MetaVia Inc.

Exclusive license grants MThera rights to develop and commercialize NB-01 for painful diabetic neuropathy.
MThera may conduct a Phase 3 trial in the U.S. and South Korea; NeuroBo to focus on DA-1726 and DA-1241.
Phase 2 efficacy data cited by MThera; financial terms not disclosed.
NeuroBo CEO says deal reflects commitment to out-license legacy assets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.